Translation

Notice: This document is an excerpt translation of the original Japanese document and is only for reference purposes. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

Consolidated Financial Results for the Six Months Ended September 30, 2026 (Under Japanese GAAP)

November 13, 2026

Company name	Kusurinomadoguchi, Inc.			Listing	Tokyo
Securities code	5592			URL	https://kusurinomadoguchi.co.jp/
Representative	(Title)	President and Representative Director	(Name)	Koji Tsutsumi	
Inquiries	(Title)	General Manager, Administration Division	(Name)	Naoto Masuda	(TEL) 03-6712-7406
Semi-annual report filing date (scheduled)		November 13, 2026	Dividend payment date (scheduled)		—

Supplementary materials prepared : Yes

Financial results briefing held : No

(Amounts of less than one million yen are rounded down)

1. Consolidated Financial Results for 1H FY3/2027 (April 1, 2026 – September 30, 2026)

(1) Consolidated Operating Results (Cumulative)

(% figures represent YoY changes)

	Revenue		Operating profit		Ordinary profit		Net income attributable to owners of the parent	
	Millions of Yen	%	Millions of Yen	%	Millions of Yen	%	Millions of Yen	%
1H FY3/2027	7,236	24.2	1,513	19.9	1,506	20.3	1,505	△7.1
1H FY3/2026	5,825	7.0	1,262	32.9	1,252	35.7	1,620	190.5

(Note) Comprehensive income: 1H FY3/2027 1,530 million yen (△8.2%); 1H FY3/2026 1,667 million yen (202.0%)

	Net income per share	Diluted net income per share
	Yen	Yen
1H FY3/2027	132.71	131.74
1H FY3/2026	145.00	142.83

(2) Consolidated Financial Position

	Total assets	Net assets	Equity ratio
	Millions of Yen	Millions of Yen	%
1H FY3/2027	26,649	11,369	42.6
FY3/2026	17,816	11,464	63.7

(Reference) Shareholders' equity: 1H FY3/2027 11,357 million yen; FY3/2026 11,352 million yen

2. Dividends

	Annual dividends per share				
	Q1-end	Q2-end	Q3-end	Year-end	Total
	Yen	Yen	Yen	Yen	Yen
FY3/2026	—	0.00	—	38.00	38.00
FY3/2027	—	0.00			
FY3/2027 (Forecast)			—	40.00	40.00

(Note) Revisions to the most recently announced dividend forecast : No

3. Consolidated Earnings Forecast for FY3/2027 (April 1, 2026 – March 31, 2027)

(% figures represent YoY changes)

	Revenue		Operating profit		Ordinary profit		Net income attributable to owners of the parent		Net income per share
	Millions of Yen	%	Millions of Yen	%	Millions of Yen	%	Millions of Yen	%	Yen
Full year	14,400	16.8	3,100	15.6	3,100	16.3	3,100	5.0	270.53

(Note) Revisions to the most recently announced earnings forecast : No

* Notes

(1) Significant changes in the scope of consolidation during the interim period : Yes

New	3cos.	(Company names)	Techno Network Co., Ltd. Keiing Co.,Ltd. blankpad, Inc.	Excluded	—cos.	(Company names)	—

The Company acquired all shares of Techno Network Co., Ltd. and blankpad, Inc., and has included them in the scope of consolidation. In addition, as Techno Network Co., Ltd. has become a wholly-owned subsidiary, its wholly-owned subsidiary Keiing Co.,Ltd. has also been included in the scope of consolidation.

(2) Application of accounting treatments specific to the preparation of interim consolidated financial statements : No

(3) Changes in accounting policies, changes in accounting estimates and restatements

(i) Changes in accounting policies due to revisions of accounting standards, etc. : No

(ii) Changes in accounting policies other than (i) : No

(iii) Changes in accounting estimates : No

(iv) Restatements : No

(4) Number of shares issued (common shares)

(i) Number of shares issued at end of period (including treasury shares)	1H FY3/2027	11,459,482shs.	FY3/2026	11,458,582shs.
(ii) Number of treasury shares at end of period	1H FY3/2027	282,400shs.	FY3/2026	—shs.
(iii) Average number of shares during the period (interim period)	1H FY3/2027	11,340,409shs.	1H FY3/2026	11,177,649shs.

※ This interim financial results summary is not subject to review by certified public accountants or an audit firm.

※ Explanation regarding the appropriate use of earnings forecasts and other special notes

The forward-looking statements in this document, including earnings forecasts, are based on information currently available to the Company and certain assumptions that the Company considers reasonable, and the Company does not guarantee their achievement. Actual results may differ materially due to various factors.

○ Table of Contents of Attachments

1. Overview of Operating Results, etc. 2
(1) Overview of Operating Results for the Interim Period 2
(2) Overview of Financial Position for the Interim Period 2
(3) Explanation of Forward-Looking Information Including Consolidated Earnings Forecast 3
2. Interim Consolidated Financial Statements and Principal Notes 4
(1) Interim Consolidated Balance Sheet 4
(2) Interim Consolidated Statement of Income and Comprehensive Income 6
Interim Consolidated Statement of Income 6
Interim Consolidated Statement of Comprehensive Income 7
(3) Interim Consolidated Statement of Cash Flows 8
(4) Notes to Interim Consolidated Financial Statements 10
(Notes on Going Concern Assumption) 10
(Notes on Significant Changes in Shareholders' Equity) 10
(Segment Information, etc.) 10

1. Overview of Operating Results, etc.

(1) Overview of Operating Results for the Interim Period

During the interim period under review, Japan's economy continued to face an uncertain outlook, affected by soaring global raw material prices as well as the situation in the Middle East.

While the social security-related budget for fiscal 2026 increased overall, the drug price revision generally lowered drug prices. Dispensing pharmacies face growing difficulty in securing drug price margins and are increasingly required to improve operational efficiency and promote the DX of their systems, including initiatives for community-based integrated care systems and family pharmacies, as well as support for online eligibility verification and electronic prescriptions.

Against this market backdrop, the Group, which offers a variety of services and products utilizing IT and AI technologies in the healthcare sector, including dispensing pharmacies, expects favorable conditions to continue.

The Group worked to increase the number of Online prescription acceptances in the Healthcare Automation Business, the pharmaceutical GMV of dispensing pharmacies and medical institutions in Everyone's Medicine Box Business, and the number of system users in the Core Systems Business, all of which are key management indicators, while also striving to create added value by strengthening the linkage of data accumulated in each business.

As a result, in the interim period under review, in addition to the continued steady accumulation of Recurring revenue in the three businesses, Medi web Co.,Ltd., which became a consolidated subsidiary in the previous fiscal year, contributed to results from the beginning of the period, and Techno Network Co., Ltd. was newly consolidated. Consequently, revenue was ¥7,236,129 thousand (up 24.2% YoY), operating profit was ¥1,513,040 thousand (up 19.9% YoY), and ordinary profit was ¥1,506,010 thousand (up 20.3% YoY). In addition, income taxes - deferred for the interim period under review amounted to −¥136,624 thousand, and net income attributable to owners of the parent was ¥1,505,087 thousand (down 7.1% YoY).

(2) Overview of Financial Position for the Interim Period

Current assets at the end of the interim period under review increased by ¥7,989,064 thousand from the end of the previous fiscal year to ¥18,079,986 thousand. This was mainly due to a ¥7,650,757 thousand increase in cash and deposits.

Non-current assets amounted to ¥8,569,462 thousand, an increase of ¥843,401 thousand from the end of the previous fiscal year. This was mainly due to a ¥294,277 thousand decrease in software, offset by increases of ¥312,422 thousand in goodwill and ¥394,116 thousand in investment securities.

As a result, total assets increased by ¥8,832,465 thousand from the end of the previous fiscal year to ¥26,649,449 thousand.

Current liabilities increased by ¥8,929,854 thousand from the end of the previous fiscal year to ¥14,133,490 thousand. This was mainly due to a ¥9,004,547 thousand increase in accounts payable - other.

Non-current liabilities amounted to ¥1,146,106 thousand, a decrease of ¥2,634 thousand from the end of the previous fiscal year. This was mainly due to a ¥34,278 thousand increase in long-term borrowings, offset by a ¥61,099 thousand decrease in long-term deferred income included in “Other.”

As a result, total liabilities increased by ¥8,927,219 thousand from the end of the previous fiscal year to ¥15,279,597 thousand.

Net assets decreased by ¥94,754 thousand from the end of the previous fiscal year to ¥11,369,851 thousand. This was mainly due to a ¥690,623 thousand increase in treasury shares and a ¥403,016 thousand decrease in capital surplus, partially offset by a ¥1,069,790 thousand increase in retained earnings.

(Cash Flows)

Cash and cash equivalents (hereinafter “funds”) at the end of the interim period under review increased by ¥7,654,949 thousand from the end of the previous fiscal year to ¥12,892,662 thousand. The status of each category of cash flows during the interim period under review and the factors behind them are as follows.

(Cash flows from operating activities)

Net cash provided by operating activities was ¥10,884,127 thousand (¥1,068,426 thousand provided in the same period of the previous year). The main increases were interim net income before income taxes of ¥1,501,260 thousand, depreciation of ¥750,661 thousand (¥681,888 thousand in the same period of the previous year) and an increase in accounts payable - other of ¥9,005,345 thousand (a decrease of ¥305,986 thousand in the same period of the previous year), while the main decrease was an increase in trade receivables of ¥278,881 thousand (an increase of ¥45,990 thousand in the same period of the previous year).

(Cash flows from investing activities)

Net cash used in investing activities was ¥1,401,591 thousand (¥1,463,411 thousand used in the same period of the previous year). This was mainly due to purchase of intangible assets (software, etc.) of ¥583,385 thousand (¥900,118 thousand used in the same period of the previous year), purchase of shares of subsidiaries resulting in change in scope of consolidation of ¥463,993 thousand, and purchase of investment securities of ¥345,773 thousand (¥73,866 thousand used in the same period of the previous year).

(Cash flows from financing activities)

Net cash used in financing activities was ¥1,827,586 thousand (¥245,039 thousand provided in the same period of the previous year). This was mainly due to purchase of treasury shares of ¥694,076 thousand (¥1,007,671 thousand used in the same period of the previous year), an increase in deposits for purchase of treasury shares of ¥109,978 thousand, purchase of shares of subsidiaries not resulting in change in scope of consolidation of ¥500,188 thousand, and dividends paid of ¥433,083 thousand (¥264,765 thousand paid in the same period of the previous year).

(3) Explanation of Forward-Looking Information Including Consolidated Earnings Forecast

There are no changes to the full-year earnings forecast.

2. Interim Consolidated Financial Statements and Principal Notes

(1) Interim Consolidated Balance Sheet

(Thousands of Yen)

	Previous fiscal year (March 31, 2026)	Current interim period (September 30, 2026)
Assets		
Current assets		
Cash and deposits	5,203,879	12,854,637
Accounts receivable - trade	4,056,710	4,475,986
Other	834,223	753,511
Allowance for doubtful accounts	△3,890	△4,149
Total current assets	10,090,922	18,079,986
Non-current assets		
Property, plant and equipment	141,580	286,808
Intangible assets		
Goodwill	870,451	1,182,873
Software	3,929,164	3,634,887
Other	122,611	269,169
Total intangible assets	4,922,227	5,086,930
Investments and other assets		
Investment securities	391,412	785,528
Long-term loans receivable from shareholders, directors or employees	499,355	497,101
Deferred tax assets	1,631,758	1,768,628
Other	239,488	257,769
Allowance for doubtful accounts	△99,761	△113,304
Total investments and other assets	2,662,252	3,195,724
Total non-current assets	7,726,061	8,569,462
Total assets	17,816,983	26,649,449

(Thousands of Yen)

	Previous fiscal year (March 31, 2026)	Current interim period (September 30, 2026)
Liabilities		
Current liabilities		
Accounts payable - trade	201,411	169,808
Short-term borrowings	2,000,000	2,000,000
Accounts payable - other	1,339,178	10,343,726
Income taxes payable	153,725	174,715
Provisions	209,391	113,345
Other	1,299,930	1,331,895
Total current liabilities	5,203,636	14,133,490
Non-current liabilities		
Long-term borrowings	821,171	855,449
Other	327,570	290,657
Total non-current liabilities	1,148,741	1,146,106
Total liabilities	6,352,377	15,279,597
Net assets		
Shareholders' equity		
Share capital	68,864	69,121
Capital surplus	4,759,565	4,356,549
Retained earnings	6,497,517	7,567,308
Treasury shares	—	△690,623
Total shareholders' equity	11,325,947	11,302,355
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	26,647	54,761
Total accumulated other comprehensive income	26,647	54,761
Share acquisition rights	430	427
Non-controlling interests	111,579	12,307
Total net assets	11,464,605	11,369,851
Total liabilities and net assets	17,816,983	26,649,449

(2) Interim Consolidated Statement of Income and Interim Consolidated Statement of Comprehensive Income

Interim Consolidated Statement of Income

(Thousands of Yen)

	Previous interim period (From April 1, 2025 to September 30, 2025)	Current interim period (From April 1, 2026 to September 30, 2026)
Revenue	5,825,099	7,236,129
Cost of sales	2,517,018	3,110,221
Gross profit	3,308,080	4,125,908
Selling, general and administrative expenses	2,045,903	2,612,868
Operating profit	1,262,177	1,513,040
Non-operating income		
Interest and dividend income	3,189	12,580
Share of profit of entities accounted for using equity method	15,140	6,816
Other	8,532	5,282
Total non-operating income	26,862	24,680
Non-operating expenses		
Interest expenses	1,506	23,181
Settlement payments	34,096	4,692
Other	1,297	3,836
Total non-operating expenses	36,900	31,710
Ordinary profit	1,252,139	1,506,010
Extraordinary income		
Gain on sale of non-current assets	—	885
Total extraordinary income	—	885
Extraordinary losses		
Loss on retirement of non-current assets	235	247
Office relocation expenses	—	5,387
Total extraordinary losses	235	5,635
Interim net income before income taxes	1,251,903	1,501,260
Income taxes - current	108,696	135,153
Income taxes - deferred	△501,486	△136,624
Total income taxes	△392,790	△1,470
Interim net income	1,644,693	1,502,731
Interim net income (loss) attributable to non-controlling interests	23,823	△2,356
Net income attributable to owners of the parent	1,620,870	1,505,087

Interim Consolidated Statement of Comprehensive Income

(Thousands of Yen)

	Previous interim period (From April 1, 2025 to September 30, 2025)	Current interim period (From April 1, 2026 to September 30, 2026)
Interim net income	1,644,693	1,502,731
Other comprehensive income		
Valuation difference on available-for-sale securities	22,983	28,113
Total other comprehensive income	22,983	28,113
Interim comprehensive income	1,667,677	1,530,844
(Breakdown)		
Interim comprehensive income attributable to owners of the parent	1,643,853	1,533,200
Interim comprehensive income attributable to non-controlling interests	23,823	△2,356

(3) Interim Consolidated Statement of Cash Flows

(Thousands of Yen)

	Previous interim period (From April 1, 2025 to September 30, 2025)	Current interim period (From April 1, 2026 to September 30, 2026)
Cash flows from operating activities		
Interim net income before income taxes	1,251,903	1,501,260
Depreciation	681,888	750,661
Amortization of goodwill	39,345	74,793
Increase (decrease) in allowance for doubtful accounts	7,618	13,200
Increase (decrease) in provision for bonuses	△31,454	△34,280
Increase (decrease) in provision for bonuses for directors (and other officers)	△13,200	△38,550
Increase (decrease) in provision for sales promotion expenses	△1,297	△954
Increase (decrease) in provision for sales discounts	△4,521	△22,259
Interest expenses	1,506	23,181
Share of loss (profit) of entities accounted for using equity method	△15,140	△6,816
Other non-operating loss (income)	△4,452	△13,054
Decrease (increase) in trade receivables	△45,990	△278,881
Increase (decrease) in trade payables	△25,800	△74,462
Loss (gain) on sale of non-current assets	—	△885
Loss on retirement of non-current assets	235	247
Decrease (increase) in accounts receivable - other	△9,114	38,185
Increase (decrease) in accounts payable - other	△305,986	9,005,345
Decrease (increase) in other assets	△39,170	18,361
Increase (decrease) in other liabilities	△80,254	△92,758
Other	1,633	5,905
Subtotal	1,407,747	10,868,239
Interest and dividends received	2,861	12,580
Interest paid	△3,282	△23,154
Income taxes refund (paid)	△338,898	26,462
Net cash provided by (used in) operating activities	1,068,426	10,884,127
Cash flows from investing activities		
Purchase of property, plant and equipment	△12,382	△11,077
Proceeds from sale of property, plant and equipment	—	1,191
Purchase of investment securities	△73,866	△345,773
Proceeds from sale of investment securities	490	—
Purchase of intangible assets	△900,118	△583,385
Proceeds from redemption of investment securities	50,000	—
Purchase of shares of subsidiaries resulting in change in scope of consolidation	—	△463,993
Loans advanced	△6,000	—
Loans advanced to directors (and other officers) and employees	△522,716	—
Proceeds from collection of loans receivable	—	3,056
Decrease (increase) in investments and other assets	1,181	△1,608
Net cash provided by (used in) investing activities	△1,463,411	△1,401,591

(Thousands of Yen)

	Previous interim period (From April 1, 2025 to September 30, 2025)	Current interim period (From April 1, 2026 to September 30, 2026)
Cash flows from financing activities		
Proceeds from short-term borrowings	1,000,000	—
Repayments of short-term borrowings	△1,000,000	—
Proceeds from long-term borrowings	1,000,000	—
Repayments of long-term borrowings	△17,676	△89,073
Proceeds from issuance of shares resulting from exercise of share acquisition rights	—	510
Purchase of treasury shares	△1,007,671	△694,076
Decrease (increase) in deposits for purchase of treasury shares	—	△109,978
Proceeds from disposal of treasury shares	535,680	—
Dividends paid	△264,765	△433,083
Repayments of finance lease liabilities	△528	△1,697
Purchase of shares of subsidiaries not resulting in change in scope of consolidation	—	△500,188
Net cash provided by (used in) financing activities	245,039	△1,827,586
Net increase (decrease) in cash and cash equivalents	△149,945	7,654,949
Cash and cash equivalents at beginning of period	2,104,095	5,237,712
Cash and cash equivalents at end of interim period	1,954,149	12,892,662

(4) Notes to Interim Consolidated Financial Statements

(Notes on Going Concern Assumption)

Not applicable.

(Notes on Significant Changes in Shareholders' Equity)

Based on resolutions of the Board of Directors meetings held on June 5, 2026 and June 29, 2026, the Company acquired 282,400 treasury shares. As a result, treasury shares increased by ¥690,623 thousand during the interim period under review and amounted to ¥690,623 thousand at the end of the interim period under review.

(Segment Information, etc.)

As the Group operates in a single segment providing solutions for pharmacies, medical care and nursing care, segment information is omitted.